Table 5. Multiple regression analysis that correlates the effect of the variant KIF6 on the HDL cholesterol concentration adjusted by statistically significant covariates.

Change in Serum HDL Cholesterol concentration after treatment; (%)
Treatment	Model	Variables	B + CI (95%)	P
Simvastatin+Atorvastatin+Rosuvastatin	Additive	Genotypes: TT, TC, and CC	0.3 (-3.8 to 4.6)	0.860
		Initial concentration of c-HDL	-26.6 (-33.4 to -19.8)	3.4x10-13*
Simvastatin+ Atorvastatin	Additive	Genotypes: TT, TC, and CC	1.0 (-3.5 to 5.6)	0.661
		Initial concentration of c-HDL	-28.7 (-36.1 to -21.3)	7.1x10-13*
Simvastatin	Additive	Genotypes: TT, TC, and CC	1.4 (-4.8 to7.7)	0.648
		Initial concentration of c-HDL	-31.9 (-42.2 to -21.6)	1.39x10-8*
Atorvastatin	Additive	Genotypes: TT, TC, and CC	0.6 (-6.3 to 7.5)	0.857
		Initial concentration of c-HDL	-25.4 (-36.4 to -14.4)	1.18x10-5*
Rosuvastatin	Additive	Genotypes: TT, TC, and CC	-11.3 (-21.5 to -1.2)	0.030*
		Current tobacco use	-36.3 (-60.1 a -12.5)	0.004*
	Dominant	KIF6 (C compared to TT)	-21.9 (-37.6 to -6.2)	0.008*
		Current tobacco use	-41.9 (-65.7 to 18.0)	0.001*

B+CI (95%) = coefficient B + a 95% confidence interval

* indicates statistical significance.